难治性-话题@MedSci

#难治性#

683篇内容 | 2688人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1528742, encodeId=e08f1528e42c2, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur Arch Otorhinolaryngol：难治性突发感音神经性听力损失中鼓室内类固醇注射与高压氧治疗的比较, objectType=article, longId=209414, objectId=4e532094144b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e532094144b, replyNumber=0, likeNumber=82, createdTime=2021-04-05, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e532094144b, moduleTitle=Eur Arch Otorhinolaryngol：难治性突发感音神经性听力损失中鼓室内类固醇注射与高压氧治疗的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e532094144b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528741, encodeId=99ac1528e415e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, objectType=article, longId=208782, objectId=0413208e8273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0413208e8273, replyNumber=0, likeNumber=69, createdTime=2021-03-22, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0413208e8273, moduleTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0413208e8273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528740, encodeId=e1951528e4066, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期, objectType=article, longId=208561, objectId=5df320856197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5df320856197, replyNumber=0, likeNumber=68, createdTime=2021-03-19, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5df320856197, moduleTitle=Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5df320856197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528739, encodeId=16fc1528e39f9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, objectType=article, longId=208223, objectId=84b3208223f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b3208223f8, replyNumber=0, likeNumber=86, createdTime=2021-03-11, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b3208223f8, moduleTitle=J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b3208223f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528738, encodeId=c8c71528e3865, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, objectType=article, longId=207913, objectId=49ca20e9132b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ca20e9132b, replyNumber=0, likeNumber=57, createdTime=2021-03-07, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ca20e9132b, moduleTitle=BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ca20e9132b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528737, encodeId=67931528e3739, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, objectType=article, longId=207517, objectId=3e5020e5170d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5020e5170d, replyNumber=0, likeNumber=61, createdTime=2021-02-25, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5020e5170d, moduleTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5020e5170d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528736, encodeId=b0451528e3637, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效, objectType=article, longId=207387, objectId=dc5120e387fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc5120e387fe, replyNumber=0, likeNumber=68, createdTime=2021-02-22, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc5120e387fe, moduleTitle=Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc5120e387fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528735, encodeId=42661528e354e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, objectType=article, longId=207377, objectId=cb8020e3772b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb8020e3772b, replyNumber=0, likeNumber=60, createdTime=2021-02-22, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb8020e3772b, moduleTitle=Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb8020e3772b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528734, encodeId=c8b31528e3442, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Clin Cancer Res：VLA4靶向纳米颗粒可有效靶向治疗耐药的难治性骨髓瘤！, objectType=article, longId=207343, objectId=096c20e34303, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=096c20e34303, replyNumber=0, likeNumber=96, createdTime=2021-02-21, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=096c20e34303, moduleTitle=Clin Cancer Res：VLA4靶向纳米颗粒可有效靶向治疗耐药的难治性骨髓瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=096c20e34303)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528733, encodeId=34cf1528e3397, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤, objectType=article, longId=207301, objectId=436420e30131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=436420e30131, replyNumber=0, likeNumber=100, createdTime=2021-02-20, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=436420e30131, moduleTitle=Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=436420e30131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528732, encodeId=6d871528e320c, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=AGA指南更新：以最少尝试实现根除难治性幽门螺杆菌感染, objectType=article, longId=207221, objectId=ff1520e22188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff1520e22188, replyNumber=0, likeNumber=16, createdTime=2021-02-19, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff1520e22188, moduleTitle=AGA指南更新：以最少尝试实现根除难治性幽门螺杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff1520e22188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528731, encodeId=eb081528e31b6, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, objectType=article, longId=207128, objectId=b43f20e12849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43f20e12849, replyNumber=0, likeNumber=92, createdTime=2021-02-16, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43f20e12849, moduleTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43f20e12849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528730, encodeId=30741528e3024, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=62, createdTime=2021-02-11, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528729, encodeId=05d81528e29fa, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Dig Dis Sci：结肠镜下粪便菌群移植（FMT）优于灌肠和鼻胃管的方式治疗艰难梭菌难治性感染, objectType=article, longId=206950, objectId=085f20695011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=085f20695011, replyNumber=0, likeNumber=69, createdTime=2021-02-10, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=085f20695011, moduleTitle=Dig Dis Sci：结肠镜下粪便菌群移植（FMT）优于灌肠和鼻胃管的方式治疗艰难梭菌难治性感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=085f20695011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528728, encodeId=a7e41528e28fa, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=75, createdTime=2021-02-09, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528727, encodeId=3cf01528e27f9, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=如何治疗PD-1难治性眼部黑色素瘤？抗CD40抗体YH003联合Toripalimab, objectType=article, longId=206768, objectId=a740206e6806, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a740206e6806, replyNumber=0, likeNumber=66, createdTime=2021-02-06, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a740206e6806, moduleTitle=如何治疗PD-1难治性眼部黑色素瘤？抗CD40抗体YH003联合Toripalimab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a740206e6806)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528726, encodeId=40381528e2691, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=祝之明：难治性内分泌高血压的微创消融治疗, objectType=article, longId=206544, objectId=d04e206544eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d04e206544eb, replyNumber=0, likeNumber=107, createdTime=2021-02-02, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d04e206544eb, moduleTitle=祝之明：难治性内分泌高血压的微创消融治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d04e206544eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528725, encodeId=94761528e2597, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, objectType=article, longId=206332, objectId=f55120633209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f55120633209, replyNumber=0, likeNumber=78, createdTime=2021-01-29, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f55120633209, moduleTitle=J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f55120633209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528724, encodeId=bad11528e24ab, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Dig Dis Sci: 行回肠肛管吻合术的溃疡性结肠炎患者感染难治性梭状芽胞杆菌和巨细胞病毒的复发率分析, objectType=article, longId=205778, objectId=8b98205e78cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b98205e78cc, replyNumber=0, likeNumber=79, createdTime=2021-01-17, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b98205e78cc, moduleTitle=Dig Dis Sci: 行回肠肛管吻合术的溃疡性结肠炎患者感染难治性梭状芽胞杆菌和巨细胞病毒的复发率分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b98205e78cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, objectTitle=Brit J Cancer：二甲双胍联合伊立替康治疗难治性大肠癌疗效分析, objectType=article, longId=205402, objectId=f5e1205402f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5e1205402f8, replyNumber=0, likeNumber=65, createdTime=2021-01-08, rootId=0, userName=freve, userId=a1ef11916292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5e1205402f8, moduleTitle=Brit J Cancer：二甲双胍联合伊立替康治疗难治性大肠癌疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5e1205402f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

难治性

2020-05-29

freve (审核中...)

前往app查看评论内容

#难治性#

Eur Arch Otorhinolaryngol：难治性突发感音神经性听力损失中鼓室内类固醇注射与高压氧治疗的比较

2021-04-05

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性

2021-03-22

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Oncol：派姆单抗可显著延长复发或难治性经典霍奇金淋巴瘤患者的无进展存活期

2021-03-19

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：PI3Kδ/CK1ε双重抑制剂Umbralisib用于治疗复发性/难治性惰性淋巴瘤

2021-03-11

freve (审核中...)

前往app查看评论内容

#难治性#

BLOOD：好消息！ISAtuximab 联合地塞米松治疗复发/难治性多发性骨髓瘤可提高ORR

2021-03-07

freve (审核中...)

前往app查看评论内容

#难治性#

Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率

2021-02-25

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：复发/难治性费城染色体阳性ALL患者采用博纳吐单抗治疗的长期疗效

2021-02-22

freve (审核中...)

前往app查看评论内容

#难治性#

Eur J Cancer：乐伐替尼可显著延长放射性碘难治性分化型甲状腺癌患者的存活期，即使已发生了肺转移！

2021-02-22

freve (审核中...)

前往app查看评论内容

#难治性#

Clin Cancer Res：VLA4靶向纳米颗粒可有效靶向治疗耐药的难治性骨髓瘤！

2021-02-21

freve (审核中...)

前往app查看评论内容

#难治性#

Cancer Discov：Venetoclax+Navitoclax+化疗治疗复发/难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤

2021-02-20

freve (审核中...)

前往app查看评论内容

#难治性#

AGA指南更新：以最少尝试实现根除难治性幽门螺杆菌感染

2021-02-19

freve (审核中...)

前往app查看评论内容

#难治性#

Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性

2021-02-16

freve (审核中...)

前往app查看评论内容

#难治性#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

freve (审核中...)

前往app查看评论内容

#难治性#

Dig Dis Sci：结肠镜下粪便菌群移植（FMT）优于灌肠和鼻胃管的方式治疗艰难梭菌难治性感染

2021-02-10

freve (审核中...)

前往app查看评论内容

#难治性#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-02-09

freve (审核中...)

前往app查看评论内容

#难治性#

如何治疗PD-1难治性眼部黑色素瘤？抗CD40抗体YH003联合Toripalimab

2021-02-06

freve (审核中...)

前往app查看评论内容

#难治性#

祝之明：难治性内分泌高血压的微创消融治疗

2021-02-02

freve (审核中...)

前往app查看评论内容

#难治性#

J Clin Oncol：新型PD-L1抑制剂Toripalimab可安全有效地治疗化疗难治性转移性鼻咽癌

2021-01-29

freve (审核中...)

前往app查看评论内容

#难治性#

Dig Dis Sci: 行回肠肛管吻合术的溃疡性结肠炎患者感染难治性梭状芽胞杆菌和巨细胞病毒的复发率分析

2021-01-17

freve (审核中...)

前往app查看评论内容

#难治性#

Brit J Cancer：二甲双胍联合伊立替康治疗难治性大肠癌疗效分析

2021-01-08

科室
- - 订阅+
  - 更多科室
工具
服务